View Future GrowthSirona Biochem 과거 순이익 실적과거 기준 점검 0/6지난 몇 년간 Sirona Biochem 의 실적에 대한 데이터가 부족합니다.핵심 정보n/a순이익 성장률n/a주당순이익(EPS) 성장률Biotechs 산업 성장률17.04%매출 성장률n/a자기자본이익률n/a순이익률n/a최근 순이익 업데이트31 Jul 2024최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Apr 23Sirona Biochem Corp. announced that it expects to receive CAD 0.4 million in fundingSirona Biochem Corp. announced a non-brokered private placement that it will issue up to 400 unsecured convertible debentures units at an issue price of CAD 1,000 per unit for the gross proceeds of up to CAD 400,000 on April 22, 2025. Each Debenture Unit will have a face value of of CAD 1,120, consisting of CAD 1,000 in principal and CAD 120 in prepaid interest. The Principal of the Debenture Units will accrue interest at a rate of 12% per annum, and such accrued interest will be paid semi-annually, in arrears. At the election of the Company, Prepaid Interest and Accrued Interest may be paid in cash or converted into Shares at a conversion price equal to the maximum Discounted Market Price equal to the maximum Discounted Market Price. The holder may, at its option, convert in full or in part, the Principal at any time prior to the maturity date, being the third anniversary of the issue date, into units of the Company at CAD 0.10 per Unit. Upon conversion of the Principal, Prepaid Interest and unpaid Accrued Interest, will be, at the election of the Company, either paid in cash or converted into Shares at the Interest Conversion Price. Each Unit will consist of one Share and one non-transferable share purchase warrant. Each Unit will consist of one Share and one non-transferable share purchase warrant at an exercise price of CAD 0.15 at any time prior to the Maturity Date. The Company shall have the right to redeem the Convertible Debentures prior to the Maturity Date at any time after 6 months from the issue date, by paying holders in cash the Face Value of the Convertible Debentures, together with all Prepaid and Accrued Interest and a redemption penalty payment of 8% of the Face Value. The closing of the Offering is subject to the receipt of necessary regulatory approvals, including the approval of the TSXV. The Convertible Debentures, Shares, Warrants and any Warrant Shares will be subject to a four month hold period under applicable securities laws and TSXV policies. The Company may pay eligible finders a fee in connection with the Offering.공시 • Apr 22Sirona Biochem Corp. announced that it expects to receive CAD 3 million in funding from Promura GmbHSirona Biochem Corp. announced that it has entered into a investment agreement with Promura GmbH to issue unsecured convertible debentures for gross proceeds of CAD 3,000,000 on April 22, 2025. The debentures will accrue interest at the rate of 12%. The company plans to compensate finders by way of cash fees and warrants. The completion of the private placement is subject to customary conditions, including acceptance from the Toronto stock exchange venture. All securities issued will be subject to a hold period in accordance with TSXV and/or other regulatory requirements.공시 • Apr 05Sirona Biochem Corp. announced that it has received CAD 0.1325 million in fundingOn April 4, 2024, Sirona Biochem Corp closed the transaction. The company has now issued 1,325,000 units at a price of CAD 0.10 per Unit for a gross proceeds of CAD 132,500. All securities issued under the Private Placement are subject to statutory hold periods expiring on August 4, 2024. No insiders participated in the private placement. No finders' fees were paid from the private placement.공시 • Feb 02Sirona Biochem Corp. announced that it expects to receive CAD 1 million in fundingSirona Biochem Corp. announced that it has entered into a private placement of promissory note for aggregate principal amount of $1,000,000 on January 29, 2024. The transaction will include participation from new lender, 0906462 B.C. Ltd. The promissory note will interest at a rate of 12% per annum. The Company has agreed to, subject to TSX Venture Exchange approval.공시 • Jan 27Sirona Biochem Corp., Annual General Meeting, Mar 28, 2024Sirona Biochem Corp., Annual General Meeting, Mar 28, 2024.공시 • Dec 12Sirona Biochem Corp. Initiates GlycoProteMim™? Trademark for Anti-Aging Molecule TFC-1326Sirona Biochem Corp. announced the trademarking of its anti-aging and anti-wrinkle molecule, TFC-1326, as GlycoProteMim. This pivotal decision marks a significant milestone in Sirona Biochem's mission to bring forth a new era of skincare innovation. The trademarking of GlycoProteMim, filed with the Instituto Nacional da Propriedade Industrial (INPI) and the United States Trademark and Patent Office, demonstrates the company's unwavering commitment to revolutionizing the cosmetics industry with cutting-edge science and unparalleled anti-aging solutions. With over two decades of research and development, Sirona Biochem has developed GlycoProteMim (TFC-1326) into a powerful solution to reverse skin aging. The molecule has proven to be a game-changer in the fight against aging, offering a diverse range of permanent benefits. Sirona Biochem has begun the trademarking process through it's subsidiary TFChem and is actively engaging industry experts to chart the most effective course for commercializing GlycoProteMim™. This strategic move underscores the company's dedication to delivering a unique and transformative anti-aging solution to the $12.5 billion global anti-aging market. The choice to trademark GlycoProteMim goes beyond a mere formality; it stands as a testament to Sirona Biochem's commitment to revolutionizing beauty through scientific innovation. Through rigorous research and clinical trials, the company firmly believes that this name will soon be associated with timeless, radiant skin. Sirona Biochem is certain that GlycoProteMim will surpass the current gold standard, Retinol, in its ability to reverse skin aging. Unlike other products on the market, GlycoProteMim provides powerful results with exceptional tolerability.공시 • Jun 29Sirona Biochem Advances Antiviral Research with New Compound Candidates for Testing At the ICGEBSirona Biochem Corp. announce the development of a promising new set of potential antiviral compounds which will undergo testing at the renowned International Centre for Genetic Engineering and Biotechnology (ICGEB). The compounds, generated by Sirona's subsidiary TFChem, are aimed at expanding Sirona's existing library of antiviral drug candidates. The ICGEB, located in Trieste, Italy, will employ specialized assays developed at their Laboratory of Molecular Virology to screen a library of 18 newly produced candidates, for their potential to inhibit SARS-CoV2. Spearheading the research program is Dr. Alessandro Marcello, a globally recognized authority in Human Virology. Building upon the previous screening results of the initial 20 compounds, these newly selected candidates hold significant promise. Testing is slated to commence within the next month. Sirona Biochem remains committed to advancing the program on antiviral research and remains optimistic about the potential impact these new compound candidates may have in combatting viral diseases.매출 및 비용 세부 내역Sirona Biochem가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:SRBC.F 매출, 비용 및 순이익 (CAD Millions)날짜매출순이익일반관리비연구개발비31 Jul 240-31130 Apr 240-21131 Jan 240-31131 Oct 230-31131 Jul 230-21130 Apr 231-22131 Jan 231-22131 Oct 221-43131 Jul 221-33130 Apr 220-43131 Jan 220-43131 Oct 210-21131 Jul 210-21130 Apr 210-31131 Jan 210-31131 Oct 200-43131 Jul 200-54130 Apr 200-54131 Jan 200-65131 Oct 190-53131 Jul 190-42130 Apr 191-22131 Jan 191-21131 Oct 181-11131 Jul 181-31130 Apr 181-41131 Jan 181-42131 Oct 170-42131 Jul 170-32130 Apr 170-32131 Jan 170-32131 Oct 160-32131 Jul 160-32130 Apr 160-32131 Jan 160-42131 Oct 150-42131 Jul 150-321양질의 수익: SRBC.F가 고품질 수익을 갖고 있는지 판단하기에는 데이터가 부족합니다.이익 마진 증가: 지난 1년 동안 SRBC.F의 이익률이 개선되었는지 판단하기에 데이터가 부족합니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 지난 5년 동안 SRBC.F의 연간 수익 성장률이 양(+)이었는지 판단하기에 데이터가 부족합니다.성장 가속화: SRBC.F의 지난해 수익 성장률을 5년 평균과 비교하기에 데이터가 부족합니다.수익 대 산업: SRBC.F의 지난 해 수익 증가율이 Biotechs 업계 평균을 상회했는지 판단하기에 데이터가 부족합니다.자기자본이익률높은 ROE: SRBC.F는 현재 수익성이 없으므로 자본 수익률이 음수(0%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/21 09:32종가2026/05/07 00:00수익2024/07/31연간 수익2023/10/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Sirona Biochem Corp.는 2명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Ellis AcklinFirst Berlin Equity Research GmbHJens HasselmeierFirst Berlin Equity Research GmbH
공시 • Apr 23Sirona Biochem Corp. announced that it expects to receive CAD 0.4 million in fundingSirona Biochem Corp. announced a non-brokered private placement that it will issue up to 400 unsecured convertible debentures units at an issue price of CAD 1,000 per unit for the gross proceeds of up to CAD 400,000 on April 22, 2025. Each Debenture Unit will have a face value of of CAD 1,120, consisting of CAD 1,000 in principal and CAD 120 in prepaid interest. The Principal of the Debenture Units will accrue interest at a rate of 12% per annum, and such accrued interest will be paid semi-annually, in arrears. At the election of the Company, Prepaid Interest and Accrued Interest may be paid in cash or converted into Shares at a conversion price equal to the maximum Discounted Market Price equal to the maximum Discounted Market Price. The holder may, at its option, convert in full or in part, the Principal at any time prior to the maturity date, being the third anniversary of the issue date, into units of the Company at CAD 0.10 per Unit. Upon conversion of the Principal, Prepaid Interest and unpaid Accrued Interest, will be, at the election of the Company, either paid in cash or converted into Shares at the Interest Conversion Price. Each Unit will consist of one Share and one non-transferable share purchase warrant. Each Unit will consist of one Share and one non-transferable share purchase warrant at an exercise price of CAD 0.15 at any time prior to the Maturity Date. The Company shall have the right to redeem the Convertible Debentures prior to the Maturity Date at any time after 6 months from the issue date, by paying holders in cash the Face Value of the Convertible Debentures, together with all Prepaid and Accrued Interest and a redemption penalty payment of 8% of the Face Value. The closing of the Offering is subject to the receipt of necessary regulatory approvals, including the approval of the TSXV. The Convertible Debentures, Shares, Warrants and any Warrant Shares will be subject to a four month hold period under applicable securities laws and TSXV policies. The Company may pay eligible finders a fee in connection with the Offering.
공시 • Apr 22Sirona Biochem Corp. announced that it expects to receive CAD 3 million in funding from Promura GmbHSirona Biochem Corp. announced that it has entered into a investment agreement with Promura GmbH to issue unsecured convertible debentures for gross proceeds of CAD 3,000,000 on April 22, 2025. The debentures will accrue interest at the rate of 12%. The company plans to compensate finders by way of cash fees and warrants. The completion of the private placement is subject to customary conditions, including acceptance from the Toronto stock exchange venture. All securities issued will be subject to a hold period in accordance with TSXV and/or other regulatory requirements.
공시 • Apr 05Sirona Biochem Corp. announced that it has received CAD 0.1325 million in fundingOn April 4, 2024, Sirona Biochem Corp closed the transaction. The company has now issued 1,325,000 units at a price of CAD 0.10 per Unit for a gross proceeds of CAD 132,500. All securities issued under the Private Placement are subject to statutory hold periods expiring on August 4, 2024. No insiders participated in the private placement. No finders' fees were paid from the private placement.
공시 • Feb 02Sirona Biochem Corp. announced that it expects to receive CAD 1 million in fundingSirona Biochem Corp. announced that it has entered into a private placement of promissory note for aggregate principal amount of $1,000,000 on January 29, 2024. The transaction will include participation from new lender, 0906462 B.C. Ltd. The promissory note will interest at a rate of 12% per annum. The Company has agreed to, subject to TSX Venture Exchange approval.
공시 • Jan 27Sirona Biochem Corp., Annual General Meeting, Mar 28, 2024Sirona Biochem Corp., Annual General Meeting, Mar 28, 2024.
공시 • Dec 12Sirona Biochem Corp. Initiates GlycoProteMim™? Trademark for Anti-Aging Molecule TFC-1326Sirona Biochem Corp. announced the trademarking of its anti-aging and anti-wrinkle molecule, TFC-1326, as GlycoProteMim. This pivotal decision marks a significant milestone in Sirona Biochem's mission to bring forth a new era of skincare innovation. The trademarking of GlycoProteMim, filed with the Instituto Nacional da Propriedade Industrial (INPI) and the United States Trademark and Patent Office, demonstrates the company's unwavering commitment to revolutionizing the cosmetics industry with cutting-edge science and unparalleled anti-aging solutions. With over two decades of research and development, Sirona Biochem has developed GlycoProteMim (TFC-1326) into a powerful solution to reverse skin aging. The molecule has proven to be a game-changer in the fight against aging, offering a diverse range of permanent benefits. Sirona Biochem has begun the trademarking process through it's subsidiary TFChem and is actively engaging industry experts to chart the most effective course for commercializing GlycoProteMim™. This strategic move underscores the company's dedication to delivering a unique and transformative anti-aging solution to the $12.5 billion global anti-aging market. The choice to trademark GlycoProteMim goes beyond a mere formality; it stands as a testament to Sirona Biochem's commitment to revolutionizing beauty through scientific innovation. Through rigorous research and clinical trials, the company firmly believes that this name will soon be associated with timeless, radiant skin. Sirona Biochem is certain that GlycoProteMim will surpass the current gold standard, Retinol, in its ability to reverse skin aging. Unlike other products on the market, GlycoProteMim provides powerful results with exceptional tolerability.
공시 • Jun 29Sirona Biochem Advances Antiviral Research with New Compound Candidates for Testing At the ICGEBSirona Biochem Corp. announce the development of a promising new set of potential antiviral compounds which will undergo testing at the renowned International Centre for Genetic Engineering and Biotechnology (ICGEB). The compounds, generated by Sirona's subsidiary TFChem, are aimed at expanding Sirona's existing library of antiviral drug candidates. The ICGEB, located in Trieste, Italy, will employ specialized assays developed at their Laboratory of Molecular Virology to screen a library of 18 newly produced candidates, for their potential to inhibit SARS-CoV2. Spearheading the research program is Dr. Alessandro Marcello, a globally recognized authority in Human Virology. Building upon the previous screening results of the initial 20 compounds, these newly selected candidates hold significant promise. Testing is slated to commence within the next month. Sirona Biochem remains committed to advancing the program on antiviral research and remains optimistic about the potential impact these new compound candidates may have in combatting viral diseases.